Aspire Biopharma Holdings Inc
ASBP0.098USD
-0.003-2.69%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
4.83MMarket Cap
LossP/E TTM
More Details of Aspire Biopharma Holdings Inc Company
Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
Aspire Biopharma Holdings Inc Info
Ticker SymbolASBP
Company nameAspire Biopharma Holdings Inc
IPO dateFeb 18, 2022
CEO- -
Number of employees- -
Security typeOrdinary Share
Fiscal year-endFeb 18
Address194 Candelaro Drive, #233
CityHUMACAO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryPuerto Rico
Postal code00791
Phone
Website
Ticker SymbolASBP
IPO dateFeb 18, 2022
CEO- -
Company Executives of Aspire Biopharma Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Kraig Higginson
Mr. Kraig Higginson
Executive Chairman of the Board
Executive Chairman of the Board
10.53M
--
Mr. Howard A. Doss, CPA
Mr. Howard A. Doss, CPA
Director
Director
400.00K
--
DR. Edward Kimball
DR. Edward Kimball
Director
Director
125.37K
+0.57%
Mr. Ernest J. Scheidemann, Jr.
Mr. Ernest J. Scheidemann, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Donald G. Fell
Mr. Donald G. Fell
Independent Director
Independent Director
--
--
Mr. Surendra Ajarapu
Mr. Surendra Ajarapu
Director
Director
--
--
Ms. Barbara J. Sher
Ms. Barbara J. Sher
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Kraig Higginson
Mr. Kraig Higginson
Executive Chairman of the Board
Executive Chairman of the Board
10.53M
--
Mr. Howard A. Doss, CPA
Mr. Howard A. Doss, CPA
Director
Director
400.00K
--
DR. Edward Kimball
DR. Edward Kimball
Director
Director
125.37K
+0.57%
Mr. Ernest J. Scheidemann, Jr.
Mr. Ernest J. Scheidemann, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Donald G. Fell
Mr. Donald G. Fell
Independent Director
Independent Director
--
--
Mr. Surendra Ajarapu
Mr. Surendra Ajarapu
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Higginson (Kraig)
9.80%
Friedman (Lance)
2.05%
Ajjarapu (Surendra K)
1.04%
Crewe Advisors LLC
0.76%
Scheidemann (Ernest J. Jr.)
0.52%
Other
85.82%
Shareholders
Shareholders
Proportion
Higginson (Kraig)
9.80%
Friedman (Lance)
2.05%
Ajjarapu (Surendra K)
1.04%
Crewe Advisors LLC
0.76%
Scheidemann (Ernest J. Jr.)
0.52%
Other
85.82%
Shareholder Types
Shareholders
Proportion
Individual Investor
13.96%
Corporation
6.69%
Investment Advisor
2.33%
Investment Advisor/Hedge Fund
0.30%
Hedge Fund
0.22%
Research Firm
0.03%
Venture Capital
0.03%
Other
76.44%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
63
3.12M
4.40%
--
2025Q3
65
3.12M
11.03%
+825.14K
2025Q2
62
2.05M
9.35%
+603.03K
2025Q1
98
1.44M
45.11%
-19.31M
2024Q4
95
589.74K
302.57%
-13.72K
2024Q3
102
603.46K
307.62%
-79.18K
2024Q2
105
682.64K
311.95%
-1.09M
2024Q1
104
1.77M
266.21%
-22.17M
2023Q4
100
1.85M
266.31%
-691.34K
2023Q3
98
2.54M
279.18%
-380.89K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Higginson (Kraig)
10.53M
21.26%
+4.36M
+70.67%
Sep 25, 2025
Friedman (Lance)
2.21M
4.46%
-1.66M
-42.98%
May 06, 2025
Ajjarapu (Surendra K)
1.12M
2.26%
+1.12M
--
Sep 25, 2025
Crewe Advisors LLC
626.85K
1.27%
+313.43K
+100.00%
Jun 30, 2025
Scheidemann (Ernest J. Jr.)
564.17K
1.14%
+3.21K
+0.57%
Sep 25, 2025
Procyon Advisors, LLC
648.41K
1.31%
+549.91K
+558.29%
Jun 30, 2025
The Vanguard Group, Inc.
80.21K
0.16%
--
--
Aug 31, 2025
Doss (Howard A)
400.00K
0.81%
+400.00K
--
Sep 25, 2025
Optivise Advisory Services, LLC
235.11K
0.47%
+128.66K
+120.87%
Jun 30, 2025
Geode Capital Management, L.L.C.
173.38K
0.35%
-11.75K
-6.35%
Aug 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
SPAC and New Issue ETF
0%
SPAC and New Issue ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Aspire Biopharma Holdings Inc?
The top five shareholders of Aspire Biopharma Holdings Inc are:
Higginson (Kraig) holds 10.53M shares, accounting for 21.26% of the total shares.
Friedman (Lance) holds 2.21M shares, accounting for 4.46% of the total shares.
Ajjarapu (Surendra K) holds 1.12M shares, accounting for 2.26% of the total shares.
Crewe Advisors LLC holds 626.85K shares, accounting for 1.27% of the total shares.
Scheidemann (Ernest J. Jr.) holds 564.17K shares, accounting for 1.14% of the total shares.
Higginson (Kraig) holds 10.53M shares, accounting for 21.26% of the total shares.
Friedman (Lance) holds 2.21M shares, accounting for 4.46% of the total shares.
Ajjarapu (Surendra K) holds 1.12M shares, accounting for 2.26% of the total shares.
Crewe Advisors LLC holds 626.85K shares, accounting for 1.27% of the total shares.
Scheidemann (Ernest J. Jr.) holds 564.17K shares, accounting for 1.14% of the total shares.
What are the top three shareholder types of Aspire Biopharma Holdings Inc?
The top three shareholder types of Aspire Biopharma Holdings Inc are:
Higginson (Kraig)
Friedman (Lance)
Ajjarapu (Surendra K)
Higginson (Kraig)
Friedman (Lance)
Ajjarapu (Surendra K)
How many institutions hold shares of Aspire Biopharma Holdings Inc (ASBP)?
As of 2025Q4, 63 institutions hold shares of Aspire Biopharma Holdings Inc, with a combined market value of approximately 3.12M, accounting for 4.40% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -6.62%.
What is the biggest source of revenue for Aspire Biopharma Holdings Inc?
In --, the -- business generated the highest revenue for Aspire Biopharma Holdings Inc, amounting to -- and accounting for --% of total revenue.
